CANY
SGMO

Caxton Associates (New York)’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Caxton Associates (New York)’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-177,960
Closed -$231K – 579
2023
Q2 		$231K Sell
177,960
-110,258
-38% -$151K 0.03% 392
2023
Q1 		$507K Buy
288,218
+123,145
+75% +$351K 0.08% 263
2022
Q4 		$518K Buy
+165,073
New +$641K 0.03% 229
2022
Q3 		– Sell
-88,549
Closed -$367K – 650
2022
Q2 		$367K Hold
88,549
– – 0.04% 334
2022
Q1 		$514K Buy
+88,549
New +$526K 0.04% 244

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caxton Associates (New York)'s SGMO Position: Q3 2023 in Review

Caxton Associates (New York) sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2023, closing a stake of 177,960 shares — an estimated $231K sold.

Caxton Associates (New York) first reported a position in SGMO in Q1 2022 and held it in 5 quarters. The position peaked at $518K in Q4 2022. 134 funds tracked by Wall St. Rank hold SGMO as of Q3 2023.

  • Caxton Associates (New York) reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 177,960 SANGAMO THERAPEUTICS INC shares in Q3 2023, an estimated $231K.
  • Caxton Associates (New York) first reported a position in SANGAMO THERAPEUTICS INC in Q1 2022 and held it in 5 quarters.
  • Caxton Associates (New York)'s SANGAMO THERAPEUTICS INC position peaked at $518K in Q4 2022.
  • 134 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.